Abstract:
The present invention relates to novel oxazolidinone compounds of the general formula (I) where R , R , R , Y , Y , Y , Y , and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
Abstract:
The present invention relates to novel oxazolidinone compounds of the general formula (I). where R 1 , R 2 , R 3 , Y 1 , Y 2 , Y 3 , and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
Abstract:
The present invention relates to novel oxazolidinone compounds of the general formula (I). where R 1 , R 2 , R 3 , Y 1 , Y 2 , Y 3 , and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
Abstract:
The present invention relates to novel oxazolidinone compounds of the general formula (I). where R 1 , R 2 , R 3 , Y 1 , Y 2 , Y 3 , and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
Abstract:
The present invention relates to novel oxazolidinone compounds of the general formula (I). where R 1 , R 2 , R 3 , Y 1 , Y 2 , Y 3 , and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
Abstract:
The present invention relates to novel oxazolidinone compounds of the general formula (I) where R1, R2, R3, Y1, Y1, Y2, Y3, and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
Abstract:
The present invention relates to novel oxazolidinone compounds of the general formula (I). where R 1 , R 2 , R 3 , Y 1 , Y 2 , Y 3 , and Z are as defined in the description; their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them.